Overview

• AstraZeneca agreed to offer discounted medicines for Medicaid in exchange for a three-year exemption from U.S. import tariffs, according to President Trump and CEO Pascal Soriot.
• Pascal Soriot said some AstraZeneca drugs will be sold on the planned TrumpRx website with discounts of up to 80 percent, with launch targeted for next year.
• AstraZeneca committed about $50 billion for U.S. production and research and development investments as part of the publicized commitments.
• The White House is presenting the AstraZeneca pact as a template following a recent Pfizer agreement, which included participation in TrumpRx and manufacturer-direct discounts cited at 50 percent.
• Trump said AstraZeneca would price drugs at the lowest levels found in most-favored countries and claimed inhaler prices would drop by an average of 654 percent, while operational details for TrumpRx and insurance handling remain unclear.